In 2023, sales of antihypertensive medicine in Sweden stood at a lower baseline compared to forecasted figures for 2024, which starts at 3.1 US Dollars Per Capita. From 2024 to 2028, there is a steady increase in sales, with a minor year-on-year growth observed. Specifically, from 2024 to 2025, the value increases by approximately 3.2%. This trend continues with stable figures from 2025 to 2027, followed by a slight increase of approximately 3.1% in 2028.

Future trends to watch for include:

Advancements in medical technology and new drug development
Changes in government policies regarding healthcare funding
Demographic shifts, particularly an aging population which may increase the prevalence of hypertension
Potential impacts of lifestyle changes and public health initiatives aimed at cardiovascular health